News and Trends

Life sciences company Mission Bio, Inc. has announced the availability of the industry’s first assay capable of determining measurable residual disease (MRD) in cancer down to the level of individual cells. Mission Bio said this heralds a new era for the understanding of disease progression. The single-cell multi-omics MRD (scMRD) assay for acute myeloid leukemia […]

U.S. biopharma company AbbVie has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ) for the treatment of adult patients with moderately to severely active Crohn’s disease. “Crohn’s disease can be debilitating and have a significant impact on a person’s daily life,” […]

Spanish biopharma company Oryzon Genomics, S.A. is starting a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, to explore Oryzon’s histone deacetylase 6 (HDAC6) inhibitors. HDAC6 inhibitors have been previously described as potentially effective treatments for CMT. Oryzon has recently […]